trending Market Intelligence /marketintelligence/en/news-insights/trending/e-mv8nw6bgnikaj0fkarww2 content esgSubNav
In This List

Sanofi, Lexicon Pharmaceuticals seek approval for diabetes drug in US, Europe

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Sanofi, Lexicon Pharmaceuticals seek approval for diabetes drug in US, Europe

Sanofi filed a new drug application to the U.S. Food and Drug Administration and a marketing authorization application to the European Medicines Agency for its diabetes drug sotagliflozin.

The company is seeking approval for the drug for use in combination with insulin therapy to improve glycemic control in adults with type 1 diabetes mellitus. Results of a phase 3 trial previously showed that sotagliflozin was better than placebo at treating type 1 diabetes.

Sanofi and Lexicon Pharmaceuticals Inc. are jointly developing the drug under a collaboration and license agreement signed in November 2015.